Literature DB >> 18991962

Substance abuse vaccines.

Frank M Orson1, Berma M Kinsey, Rana A K Singh, Yan Wu, Tracie Gardner, Thomas R Kosten.   

Abstract

Conventional substance-abuse treatments have only had limited success for drugs such as cocaine, nicotine, methamphetamine, and phencyclidine. New approaches, including vaccination to block the effects of these drugs on the brain, are in advanced stages of development. Although several potential mechanisms for the effects of antidrug vaccines have been suggested, the most straightforward and intuitive mechanism involves binding of the drug by antibodies in the bloodstream, thereby blocking entry and/or reducing the rate of entry of the drug into the central nervous system. The benefits of such antibodies on drug pharmacodynamics will be influenced by both the quantitative and the qualitative properties of the antibodies. The sum of these effects will determine the success of the clinical applications of antidrug vaccines in addiction medicine. This review will discuss these issues and present the current status of vaccine development for nicotine, cocaine, methamphetamine, phencyclidine, and morphine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18991962      PMCID: PMC2587140          DOI: 10.1196/annals.1441.027

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  59 in total

1.  VARIATIONS IN AFFINITIES OF ANTIBODIES DURING THE IMMUNE RESPONSE.

Authors:  H N EISEN; G W SISKIND
Journal:  Biochemistry       Date:  1964-07       Impact factor: 3.162

2.  Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats.

Authors:  J W Proksch; W B Gentry; S M Owens
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

3.  Endogenous opioid blockade and impulsive responding in alcoholics and healthy controls.

Authors:  Jennifer M Mitchell; Venessa C Tavares; Howard L Fields; Mark D'Esposito; Charlotte A Boettiger
Journal:  Neuropsychopharmacology       Date:  2006-10-18       Impact factor: 7.853

4.  A measurement of the specificities of antibodies to morphine-6-succinyl-BSA by competitive inhibition of 14 C-morphine binding.

Authors:  B H Wainer; F W Fitch; J Fried; R M Rothberg
Journal:  J Immunol       Date:  1973-03       Impact factor: 5.422

Review 5.  Opiate addiction in China: current situation and treatments.

Authors:  Yi-Lang Tang; Dong Zhao; Chengzheng Zhao; Joseph F Cubells
Journal:  Addiction       Date:  2006-05       Impact factor: 6.526

6.  Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats.

Authors:  J L Valentine; S M Owens
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

Review 7.  Immunotherapy for the treatment of drug abuse.

Authors:  Thomas Kosten; S Michael Owens
Journal:  Pharmacol Ther       Date:  2005-10       Impact factor: 12.310

8.  Delayed clearance of morphine from the circulation of rabbits immunized with morphine-6-hemisuccinate bovine serum albumin.

Authors:  J H Hill; B H Wainer; F W Fitch; R M Rothberg
Journal:  J Immunol       Date:  1975-04       Impact factor: 5.422

9.  A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents.

Authors:  Benito Anton; Philippe Leff
Journal:  Vaccine       Date:  2006-02-08       Impact factor: 3.641

Review 10.  Therapeutic vaccines for substance dependence.

Authors:  Margaret Haney; Thomas R Kosten
Journal:  Expert Rev Vaccines       Date:  2004-02       Impact factor: 5.217

View more
  42 in total

1.  New medications for substance use disorders: challenges and opportunities.

Authors:  Nora D Volkow; Phil Skolnick
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

Review 2.  Bacterial cocaine esterase: a protein-based therapy for cocaine overdose and addiction.

Authors:  Diwahar Narasimhan; James H Woods; Roger K Sunahara
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

3.  Immune to addiction: the ethical dimensions of vaccines against substance abuse.

Authors:  Michael J Young; Dominic A Sisti; Hila Rimon-Greenspan; Jason L Schwartz; Arthur L Caplan
Journal:  Nat Immunol       Date:  2012-05-18       Impact factor: 25.606

4.  New vaccine development for chronic brain disease.

Authors:  Alan Dt Barrett; Rakez Kayed; George R Jackson; Kathryn A Cunningham
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

5.  Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy.

Authors:  Katherine E Cornish; Andrew C Harris; Mark G LeSage; Dan E Keyler; Danielle Burroughs; Cathy Earley; Paul R Pentel
Journal:  Int Immunopharmacol       Date:  2011-07-28       Impact factor: 4.932

6.  Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.

Authors:  Rashmi Jalah; Oscar B Torres; Alexander V Mayorov; Fuying Li; Joshua F G Antoline; Arthur E Jacobson; Kenner C Rice; Jeffrey R Deschamps; Zoltan Beck; Carl R Alving; Gary R Matyas
Journal:  Bioconjug Chem       Date:  2015-06-05       Impact factor: 4.774

7.  Hapten optimization for cocaine vaccine with improved cocaine recognition.

Authors:  Muthu Ramakrishnan; Berma M Kinsey; Rana A Singh; Thomas R Kosten; Frank M Orson
Journal:  Chem Biol Drug Des       Date:  2014-07-29       Impact factor: 2.817

Review 8.  Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse.

Authors:  Stephen Brimijoin; Xiaoyun Shen; Frank Orson; Thomas Kosten
Journal:  Expert Rev Vaccines       Date:  2013-03       Impact factor: 5.217

9.  DBH gene as predictor of response in a cocaine vaccine clinical trial.

Authors:  Thomas R Kosten; Coreen B Domingo; Sara C Hamon; David A Nielsen
Journal:  Neurosci Lett       Date:  2013-02-28       Impact factor: 3.046

Review 10.  Reducing substance use during adolescence: a translational framework for prevention.

Authors:  Jessica J Stanis; Susan L Andersen
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.